Message #4 From:
NewsBot Date: August 8, 2006 05:30:00 AM
EVSD News Endovasc Receives US Patent Protecting Its Muscle Mass Technology
HOUSTON--(BUSINESS WIRE)--Aug. 8, 2006--Endovasc Inc. (OTCBB: EVSC, OTC: EVSD), today announced that the United States Patent and Trademark Office has granted the Company a patent entitled "Development of Muscle Mass in a Mammal." The patent number is US 7,074,812 B2.
Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer, commented, "We are extremely pleased to receive this patent protecting one of our key technologies. The expansion of our intellectual property portfolio is critical to our long-term success and this is a very positive development while we are working diligently toward the final phase of testing for our drug Liprostin."
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit www.endovasc.com.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
